Fax: (415) 502-4372
A review of preclinical and clinical data
Article first published online: 22 DEC 2009
Copyright © 2009 American Cancer Society
Volume 116, Issue 3, pages 749–757, 1 February 2010
How to Cite
DuBois, S. G., Marina, N. and Glade-Bender, J. (2010), Angiogenesis and vascular targeting in Ewing sarcoma. Cancer, 116: 749–757. doi: 10.1002/cncr.24844
We acknowledge the assistance of Kathleen Jee with graphic design.
The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
- Issue published online: 25 JAN 2010
- Article first published online: 22 DEC 2009
- Manuscript Accepted: 17 JUN 2009
- Manuscript Revised: 16 JUN 2009
- Manuscript Received: 20 APR 2009
- Ewing sarcoma;
- vascular endothelial growth factor;
Ewing sarcoma is the second most common type of bone cancer in children and young adults. In recent years, the mechanisms by which these tumors develop and maintain their vascular supply have been elucidated. Additional work has demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of Ewing sarcoma mouse xenografts. Early clinical data suggest that these results also may extend to patients with Ewing sarcoma who are treated with antiangiogenic or antivascular therapies. For the current review, the authors summarized the available data supporting this approach. Cancer 2010. © 2009 American Cancer Society.